Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinotecMDNC 24 Equity-to-Asset is 0.84 as of May. 2026, which is 56% above its 10-year median of 0.54. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medinotec's Total Stockholders Equity for the quarter that ended in May. 2026 was $5.85 Mil. Medinotec's Total Assets for the quarter that ended in May. 2026 was $6.99 Mil.
Therefore, Medinotec's Equity to Asset Ratio for the quarter that ended in May. 2026 was 0.84.
The historical rank and industry rank for Medinotec's Equity-to-Asset or its related term are showing as below:
MDNC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.36 Med: 0.54 Max: 0.84
Current: 0.84
During the past 5 years, the highest Equity to Asset Ratio of Medinotec was 0.84. The lowest was -0.36. And the median was 0.54.
MDNC's Equity-to-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.64
vs MDNC: 0.84
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medinotec Equity-to-Asset Related Terms
Medinotec Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Medinotec's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDNC vs NVNO, APYX, RDGL: Equity-to-Asset Comparison
For the Medical Devices subindustry, Medinotec's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medinotec's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medinotec's Equity to Asset Ratio for the fiscal year that ended in Feb. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinotec (MDNC) has a Equity-to-Asset of 0.84 as of May. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medinotec and its competitors. This is 56% above median its historical median of 0.54.
Is Medinotec's Equity-to-Asset too high?
Medinotec's current Equity-to-Asset of 0.84 is 56% above median its 10-year median of 0.54. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Medinotec's value of 0.84 is 31.3% above this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's Equity-to-Asset compare to NVNO and APYX?
Medinotec's Equity-to-Asset of 0.84 can be compared against companies in the Medical Devices & Instruments industry. The industry median Equity-to-Asset is 0.64. Medinotec's value of 0.84 is 31.3% above this benchmark. While the company's 10-year median is 0.54 vs. the industry median of 0.64, Medinotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current Equity-to-Asset of 0.84 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medinotec and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current Equity-to-Asset is 0.84, which is 56% above median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current Equity-to-Asset of 0.84. The current Equity-to-Asset is 0.84, which is 56% above median its 10-year median of 0.54 and 31.3% above the Medical Devices & Instruments industry median of 0.64. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medinotec (MDNC), the current Equity-to-Asset is 0.84 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
